Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C - PubMed (original) (raw)

Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C

C T Esmon et al. Proc Natl Acad Sci U S A. 1981 Apr.

Abstract

Perfusion of the myocardium with protein C in the presence of thrombin (EC 3.4.21.5) elicits a potent anticoagulant activity, which is identified as activated protein C on the basis of synthetic substrate hydrolysis and anticoagulant properties. The rate of activated protein C formation during the transit through the myocardium is at least 20,000 times that of thrombin-catalyzed activation of protein C in the perfusion solution. The capacity of the heart to activate protein C is maintained for at least 1 hr when thrombin is present in the perfusate, but decays (half-life approximately 30 min) once thrombin is omitted. Addition of diisopropyl-phospho-thrombin increases this decay rate more than 10-fold. Coperfusing diisopropylphospho-thrombin with active thrombin lowers the amount of protein C activation in the myocardium. Cultured monolayers of human endothelium enhance the rate of thrombin-catalyzed protein C activation. As with myocardium, the activation rate is inhibited by including diisopropylphospho-thrombin in the medium. It is proposed that the surface of vascular endothelium provides a cofactor that enhances the rate of protein C activation by thrombin.

PubMed Disclaimer

Cited by

Urinary thrombomodulin and catecholamine levels are interrelated in healthy volunteers immersed in cold and warm water.
Pakanen L, Pääkkönen T, Ikäheimo TM, Rintamäki H, Leppäluoto J, Kaija H, Kortelainen ML, Rautio A, Porvari K. Pakanen L, et al. Temperature (Austin). 2015 May 5;3(1):161-6. doi: 10.1080/23328940.2015.1033589. eCollection 2016 Jan-Mar. Temperature (Austin). 2015. PMID: 27227082 Free PMC article.
Met 358 to Arg mutation of alpha 1-antitrypsin associated with protein C deficiency in a patient with mild bleeding tendency.
Vidaud D, Emmerich J, Alhenc-Gelas M, Yvart J, Fiessinger JN, Aiach M. Vidaud D, et al. J Clin Invest. 1992 May;89(5):1537-43. doi: 10.1172/JCI115746. J Clin Invest. 1992. PMID: 1569192 Free PMC article.
Identification of the Novel Variants in Patients With Chronic Thromboembolic Pulmonary Hypertension.
Yaoita N, Satoh K, Satoh T, Shimizu T, Saito S, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Kikuchi N, Kurosawa R, Miyata S, Nagasaki M, Yasuda J, Shimokawa H. Yaoita N, et al. J Am Heart Assoc. 2020 Nov 3;9(21):e015902. doi: 10.1161/JAHA.120.015902. Epub 2020 Oct 24. J Am Heart Assoc. 2020. PMID: 33103541 Free PMC article.
Expression of thrombomodulin and consequences of thrombomodulin deficiency during healing of cutaneous wounds.
Peterson JJ, Rayburn HB, Lager DJ, Raife TJ, Kealey GP, Rosenberg RD, Lentz SR. Peterson JJ, et al. Am J Pathol. 1999 Nov;155(5):1569-75. doi: 10.1016/S0002-9440(10)65473-9. Am J Pathol. 1999. PMID: 10550314 Free PMC article.
Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?
Jourdy Y, Enjolras N, Le Quellec S, Bordet JC, Négrier C, Vinciguerra C, Dargaud Y. Jourdy Y, et al. PLoS One. 2017 Nov 16;12(11):e0188213. doi: 10.1371/journal.pone.0188213. eCollection 2017. PLoS One. 2017. PMID: 29145514 Free PMC article.

References

1. J Biol Chem. 1974 Jan 25;249(2):594-605 - PubMed
1. Biochim Biophys Acta. 1975 Oct 20;405(2):380-7 - PubMed
1. J Biol Chem. 1976 Jan 25;251(2):355-63 - PubMed
1. J Biol Chem. 1976 May 25;251(10):3052-6 - PubMed
1. Biochemistry. 1976 Nov 2;15(22):4893-900 - PubMed

Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C - PubMed (original) (raw)